Literature DB >> 27667367

EASL Recommendations on Treatment of Hepatitis C 2016.

.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27667367     DOI： 10.1016/j.jhep.2016.09.001

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  296 in total

1.  Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients.

Authors:  Giovanni Mazzola; Lucia Adamoli; Vincenza Calvaruso; Fabio Salvatore Macaluso; Pietro Colletti; Sergio Mazzola; Adriana Cervo; Marcello Trizzino; Francesco Di Lorenzo; Chiara Iaria; Tullio Prestileo; Ambrogio Orlando; Vito Di Marco; Antonio Cascio
Journal:  Infection       Date:  2018-12-05       Impact factor: 3.553

Review 2.  [Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E].

Authors:  R Bartenschlager; M Cornberg; T Pietschmann
Journal:  Internist (Berl)       Date:  2017-07       Impact factor: 0.743

3.  Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality.

Authors:  Ahmed Yahia Elmowafy; Hanzada Mohamed El Maghrabi; Khaled Farouk Eldahshan; Ayman Fathi Refaie; Mohammed Adel Elbasiony; Yasser Elsayed Matter; Hazem Hamed Saleh; Gamal Elsayed Shiha; Lionel Rostaing; Mohamed Adel Bakr
Journal:  Int Urol Nephrol       Date:  2019-07-30       Impact factor: 2.370

4.  A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DCSpecial Reporting on:• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)PLUS Meeting Abstract SummariesWith Expert Commentary by:Fred Poordad, MDChief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-12

Review 5.  Controversies in hepatitis C therapy: Reactivation of hepatitis B virus.

Authors:  Sarah R Lieber; Michael W Fried
Journal:  Clin Liver Dis (Hoboken)       Date:  2017-10-31

6.  Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.

Authors:  Matteo Nicola Dario Di Minno; Pasquale Ambrosino; Antonio Riccardo Buonomo; Biagio Pinchera; Ilenia Calcaterra; Manuel Crispo; Riccardo Scotto; Francesco Borgia; Consalvo Mattia; Ivan Gentile
Journal:  Intern Emerg Med       Date:  2019-08-08       Impact factor: 3.397

7.  Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

Authors:  Luis Margusino-Framiñán; Purificación Cid-Silva; Sandra Rotea-Salvo; Álvaro Mena-de-Cea; Francisco Suárez-López; Pilar Vázquez-Rodríguez; Manuel Delgado-Blanco; Ana Isabel Sanclaudio-Luhia; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal:  Eur J Hosp Pharm       Date:  2020-02-07

8.  Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants.

Authors:  Nadezhda T Doncheva; Francisco S Domingues; David R McGivern; Tetsuro Shimakami; Stefan Zeuzem; Thomas Lengauer; Christian M Lange; Mario Albrecht; Christoph Welsch
Journal:  J Mol Biol       Date:  2019-04-30       Impact factor: 5.469

9.  Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.

Authors:  Adel Abdel-Moneim; Alaa Aboud; Mohamed Abdel-Gabaar; Mohamed I Zanaty; Mohamed Ramadan
Journal:  Hepatol Int       Date:  2018-05-12       Impact factor: 6.047

10.  Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.

Authors:  Adel Abdel-Moneim; Alaa Aboud; Mohamed Abdel-Gabbar; Mohamed Zanaty; Mohamed Ramadan
Journal:  Dig Dis Sci       Date:  2018-03-15       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.